These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36765186)

  • 1. Immunoproteasome inhibition in CRPC.
    Stone L
    Nat Rev Urol; 2023 Mar; 20(3):130. PubMed ID: 36765186
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer.
    Li J; Liu N; Zhou H; Xian P; Song Y; Tang X; Li Y; Basler M
    Br J Cancer; 2023 Mar; 128(7):1377-1390. PubMed ID: 36681728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition.
    Koerner J; Horvath D; Oliveri F; Li J; Basler M
    Oncoimmunology; 2023; 12(1):2156091. PubMed ID: 36531689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F; Miller K
    Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy for CRPC].
    Ozono S; Furuse H
    Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.
    Kang M; Lee HS; Lee YJ; Choi WS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Urology; 2015 Jan; 85(1):273.e9-15. PubMed ID: 25440760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
    Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
    Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers.
    Wang J; Xu W; Wang B; Lin G; Wei Y; Abudurexiti M; Zhu W; Liu C; Qin X; Dai B; Wan F; Zhang H; Zhu Y; Ye D
    Cancer Lett; 2020 Aug; 485():45-55. PubMed ID: 32428663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
    Sternberg CN
    Future Oncol; 2019 May; 15(13):1437-1457. PubMed ID: 30848157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Updated treatment of castration-resistant prostate cancer].
    Xu S; Zhang ZY
    Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
    Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
    Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study.
    Angulo JC; Ciria Santos JP; Gómez-Caamaño A; Poza de Celis R; González Sala JL; García Garzón JM; Galán-Llopis JA; Pérez Sampietro M; Perrot V; Planas Morin J;
    World J Urol; 2022 Oct; 40(10):2459-2466. PubMed ID: 36057895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer(CRPC)in Japan].
    Onozawa M; Hinotsu S; Akaza H; Nakajima T;
    Gan To Kagaku Ryoho; 2021 Nov; 48(11):1359-1363. PubMed ID: 34795127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
    Luo J; Beer TM; Graff JN
    Oncology (Williston Park); 2016 Apr; 30(4):336-44. PubMed ID: 27085332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we give metformin to all men with CRPC?
    Clyne M
    Nat Rev Urol; 2014 Feb; 11(2):63. PubMed ID: 24445914
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.